论文部分内容阅读
Immune therapy: The 40 nm NINA (Normalization Inducing NAno)-particle contains a defined Quillaja saponin fraction C (QHC) with a strong immune modulating capacity by guiding immune cells to differentiation, expression of communication molecules, production of cytokines, and eventually to programmed cell death.AML cells from myeloblasts or their precursors are likewise driven along the same pathway towards programmed cell death, opening the possibility for immune therapy.Cancer therapy: AML cancer cells from the cell line HL-60 and from 12 AML patients were highly sensitive to the NINA particle i.e.a 30 to 40 fold more sensitive than normal cells of the same origin.The mode of action and target is a pathway causing the cells to exit the cell cycle among others by down regulation several cyclin dependent kinases (CDKs), cyclines and thymidine kinase.The NINA particle is well accepted by animals and humans with high bioavailability and high therapeutic index.The NINA particle has added or synergistic effects together with cytostatic drugs on AML cells.NINA particle, stand alone or in combination with other drugs, is promising for AML treatment with considerably reduced side effects compared to commercial anticancer drugs.